Aveanna Healthcare Holdings Inc. $AVAH Shares Sold by Algert Global LLC

Key Points

• Algert Global reduced its Aveanna Healthcare position by 10.3% in the second quarter, selling 184,133 shares and retaining 1.61 million shares worth approximately $13.8 million. Institutional investors collectively own 87.96% of the company.
• Aveanna exceeded quarterly expectations, reporting EPS of $0.22 versus $0.17 expected and revenue of $670.48 million versus $638.61 million. Analysts raised price targets, contributing to a “Moderate Buy” consensus and an average target of $12.89.
• Major shareholders sold substantial stakes at $11.50 per share, while insiders sold roughly $773.1 million of stock during the quarter. The sizable insider selling could create investor concerns about additional selling pressure despite the positive earnings and analyst outlook.

Algert Global LLC cut its position in shares of Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Free Report) by 10.3% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,610,747 shares of the company's stock after selling 184,133 shares during the quarter. Algert Global LLC owned 0.74% of Aveanna Healthcare worth $13,804,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd increased its position in shares of Aveanna Healthcare by 252.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company's stock valued at $27,000 after buying an additional 2,400 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Aveanna Healthcare in the 2nd quarter worth about $43,000. Summit Securities Group LLC acquired a new stake in Aveanna Healthcare in the 1st quarter valued at about $53,000. Oxford Asset Management LLP acquired a new stake in Aveanna Healthcare in the 2nd quarter valued at about $64,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in Aveanna Healthcare during the 2nd quarter valued at about $69,000. 87.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on AVAH. Royal Bank Of Canada upped their price target on shares of Aveanna Healthcare from $10.00 to $16.00 and gave the company an "outperform" rating in a report on Monday. Stephens raised Aveanna Healthcare from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $10.00 to $11.00 in a research note on Friday, May 15th. BMO Capital Markets increased their target price on Aveanna Healthcare from $10.00 to $14.00 and gave the company an "outperform" rating in a report on Friday, August 14th. Truist Financial raised their price target on Aveanna Healthcare from $11.00 to $15.00 and gave the stock a "hold" rating in a research report on Monday. Finally, Raymond James Financial upped their price objective on Aveanna Healthcare from $13.00 to $15.00 and gave the company a "strong-buy" rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $12.89.

Aveanna Healthcare Stock Performance

Aveanna Healthcare stock opened at $13.59 on Wednesday. The stock has a fifty day moving average price of $9.83 and a 200 day moving average price of $7.99. Aveanna Healthcare Holdings Inc. has a 52 week low of $5.93 and a 52 week high of $13.98. The firm has a market capitalization of $2.97 billion, a P/E ratio of 11.05, a PEG ratio of 0.96 and a beta of 1.90. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 4.47.

Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.05. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%.The firm had revenue of $670.48 million for the quarter, compared to analyst estimates of $638.61 million. Equities research analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.68 earnings per share for the current year.

Insider Buying and Selling at Aveanna Healthcare

In other news, major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares of the business's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $11.50, for a total transaction of $143,704,885.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Robert M. Williams, Jr. sold 14,500,002 shares of the company's stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $166,750,023.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 79,746,745 shares of company stock worth $773,117,091 in the last quarter. 5.30% of the stock is owned by insiders.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $16 from $10 and upgraded AVAH to “outperform.” The upgrade reinforces the bullish outlook following the stock’s recent rally. Benzinga analyst coverage
• Positive Sentiment: Truist Financial increased its price target to $15 from $11, although it maintained a “hold” rating. Other analysts have also raised targets after Aveanna exceeded quarterly earnings and revenue expectations. Benzinga analyst coverage
• Positive Sentiment: Aveanna reported quarterly EPS of $0.22 versus the $0.17 consensus estimate and revenue of $670.48 million versus expectations of $638.61 million. The earnings beat supports the improved analyst outlook and investor interest in the shares.
• Neutral Sentiment: Management will participate in the Jefferies Healthcare Services and Technology Conference on September 15. The presentation and one-on-one investor meetings could provide additional business updates, but the event is not an immediate financial catalyst. Aveanna conference announcement
• Negative Sentiment: Major shareholders, including Bain Capital- and J.H. Whitney-affiliated holders, disclosed substantial sales in a roughly $176 million offering. Additional sales by CEO Jeff Shaner, director Rodney Windley, and insider Edwin Reisz at $11.50 per share could weigh on sentiment and increase concerns about selling pressure, even though these holders retained sizable positions. Home Health Care News offering report

Aveanna Healthcare Profile

Aveanna Healthcare, Inc NASDAQ: AVAH is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna's offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.

Want to see what other hedge funds are holding AVAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source